COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study

…, G Minuti, D Moro-Sibilot, G Pasello, A Passaro… - The Lancet …, 2020 - thelancet.com
Background Early reports on patients with cancer and COVID-19 have suggested a high
mortality rate compared with the general population. Patients with thoracic malignancies are …

Overcoming therapy resistance in EGFR-mutant lung cancer

A Passaro, PA Jänne, T Mok, S Peters - Nature Cancer, 2021 - nature.com
Tyrosine kinase inhibitors (TKIs) have dramatically changed the clinical prospects of
patients with non-small cell lung cancer harboring epidermal growth factor receptor (EGFR)-…

Managing resistance to immune checkpoint inhibitors in lung cancer: treatment and novel strategies

A Passaro, J Brahmer, S Antonia, T Mok… - Journal of Clinical …, 2022 - ascopubs.org
A proportion of patients with lung cancer experience long-term clinical benefit with immune
checkpoint inhibitors (ICIs). However, most patients develop disease progression during …

Bone and brain metastasis in lung cancer: recent advances in therapeutic strategies

C D'Antonio, A Passaro, B Gori… - … in medical oncology, 2014 - journals.sagepub.com
Bone and brain metastases are a very common secondary localization of disease in patients
with lung cancer. The prognosis of these patients is still poor with a median survival of less …

[HTML][HTML] Recent advances on the role of EGFR tyrosine kinase inhibitors in the management of NSCLC with uncommon, non exon 20 insertions, EGFR mutations

A Passaro, T Mok, S Peters, S Popat, MJ Ahn… - Journal of Thoracic …, 2021 - Elsevier
The first-line treatment of choice for patients with epidermal growth factor receptor (EGFR)
mutation-positive non-small cell lung cancer (NSCLC) is an EGFR tyrosine kinase inhibitor, of …

[HTML][HTML] Severity of COVID-19 in patients with lung cancer: evidence and challenges

A Passaro, C Bestvina, MV Velez… - … for immunotherapy of …, 2021 - ncbi.nlm.nih.gov
Cancer patients are highly vulnerable to SARS-CoV-2 infections due to frequent contacts with
the healthcare system, immunocompromised state from cancer or its therapies, supportive …

[HTML][HTML] Cancer care during the spread of coronavirus disease 2019 (COVID-19) in Italy: young oncologists' perspective

M Lambertini, A Toss, A Passaro, C Criscitiello… - ESMO open, 2020 - Elsevier
At the end of 2019, a novel severe acute respiratory syndrome (SARS) coronavirus (CoV),
named SARS-CoV-2 or 2019-nCoV, has been identified as the microbial agent causing viral …

[HTML][HTML] Immunotherapy in non-small cell lung cancer harbouring driver mutations

A Addeo, A Passaro, U Malapelle, GL Banna… - Cancer treatment …, 2021 - Elsevier
… Author links open overlay panel Alfredo Addeo a , Antonio Passaro b , Umberto
Malapelle c , Giuseppe Luigi Banna d , Vivek Subbiah e , Alex Friedlaender a … Passaro, I …

Co-activation of STAT3 and YES-associated protein 1 (YAP1) pathway in EGFR-mutant NSCLC

…, M Provencio, F de Marinis, A Passaro… - JNCI: Journal of the …, 2017 - academic.oup.com
Background The efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors (TKIs) in EGFR-mutant non–small cell lung cancer (NSCLC) is limited by adaptive …

[HTML][HTML] ESMO Management and treatment adapted recommendations in the COVID-19 era: Lung cancer

A Passaro, A Addeo, C Von Garnier, F Blackhall… - ESMO open, 2020 - Elsevier
The COVID-19 pandemic, characterised by a fast and global spread during the first months
of 2020, has prompted the development of a structured set of recommendations for cancer …